The UK’s most powerful supercomputer, enabling scientists and healthcare experts to use AI and simulation to accelerate the digital biology revolution, was launched by NVIDIA today.
Ranked among the world’s top 50 fastest computers and powered by 100% renewable energy, Cambridge-1 is the first NVIDIA supercomputer designed and built for external research access. The company will collaborate with researchers to make much of this work available to the greater scientific community.
Representing a $100 million investment by NVIDIA, King’s College London and Guy’s and St Thomas’ NHS Foundation Trust are using Cambridge-1 to teach AI models to generate synthetic brain images by learning from tens of thousands of MRI brain scans, from various ages and diseases. The goal is to use this synthetic data model to gain a better understanding of diseases like dementia, stroke, brain cancer and multiple sclerosis and enable earlier diagnosis and treatment.
“Through this partnership, we will be able to use a scale of computational power that is unprecedented in healthcare research,” said Professor Sebastien Ourselin, head of the School of Biomedical Engineering & Imaging Sciences at King’s College London. “It will be truly transformational for the health and treatment of patients.”
This research leverages several of the UK’s world-leading healthcare resources through close collaboration with the National Health Service and the UK Biobank, one of the richest biomedical databases in the world. King’s College London intends to share this synthetic data model-with the greater research and startup community.
“The power of artificial intelligence in healthcare will help to speed up diagnosis for patients, improve services such as breast cancer screening, and support the way that we risk assess and prioritise patients according to clinical need,” said Professor Ian Abbs, chief executive officer of Guy’s and St Thomas’ NHS Foundation Trust. “We are excited about our involvement in the Cambridge-1 data centre as it will enable us to be amongst the first to benefit from these new AI capabilities – using the very latest technology to benefit our patients, as well as manage precious resources more efficiently.”
“Cambridge-1 will empower world-leading researchers in business and academia with the ability to perform their life’s work on the U.K.’s most powerful supercomputer, unlocking clues to disease and treatments at a scale and speed previously impossible in the UK,” said Jensen Huang, founder and CEO of NVIDIA. “The discoveries developed on Cambridge-1 will take shape in the UK, but the impact will be global, driving groundbreaking research that has the potential to benefit millions around the world.”
Featuring 80 DGX A100 systems integrating NVIDIA A100 GPUs, BlueField -2 DPUs and NVIDIA HDR InfiniBand networking, Cambridge-1 is an NVIDIA DGX SuperPOD that delivers more than 400 petaflops of AI performance and 8 petaflops of Linpack performance. The system is located at a facility operated by NVIDIA partner Kao Data.
Cambridge-1 is the first supercomputer NVIDIA has dedicated to advancing industry-specific research in the UK The company also intends to build an AI Center for Excellence in Cambridge featuring a new Arm-based supercomputer, which will support more industries across the country.